Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QH101 in Brain, Meningeal, and Spinal Cord Metastatic Malignant Solid Tumors
NCT07656103Phase 1Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- May 2026
- Primary completion
- May 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of QH101 in brain metastasis (BM), leptomeningeal metastasis (LMD) and spinal cord neoplasm (SCT), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Adverse Events at 1 year, Neurological function assessment at 12 months and 2 more. Planned start May 2026; status: not yet recruiting.
02
Drugs
QH101
03
Conditions
brain metastasis (BM)leptomeningeal metastasis (LMD)spinal cord neoplasm (SCT)
Beyond the preview
Go deeper on NCT07656103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07656103.